XERS Stock | | | USD 3.51 0.07 1.96% |
Xeris Pharmaceuticals financial indicator trend analysis is more than just analyzing Xeris Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xeris Pharmaceuticals is a good investment. Please check the relationship between Xeris Pharmaceuticals Deferred Long Term Liab and its Long Term Debt accounts. Check out
Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Xeris Stock please use our
How to Invest in Xeris Pharmaceuticals guide.
Deferred Long Term Liab vs Long Term Debt
Deferred Long Term Liab vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Xeris Pharmaceuticals Deferred Long Term Liab account and
Long Term Debt. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Xeris Pharmaceuticals' Deferred Long Term Liab and Long Term Debt is 0.88. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Xeris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Xeris Pharmaceuticals' Deferred Long Term Liab and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Xeris Pharmaceuticals are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Deferred Long Term Liab i.e., Xeris Pharmaceuticals' Deferred Long Term Liab and Long Term Debt go up and down completely randomly.
Correlation Coefficient | 0.88 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.
Long Term Debt
Long-term debt is a debt that Xeris Pharmaceuticals has held for over one year. Long-term debt appears on Xeris Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Xeris Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from Xeris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xeris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Xeris Stock please use our
How to Invest in Xeris Pharmaceuticals guide.
Enterprise Value is likely to gain to about 509.5
M in 2024, whereas
Selling General Administrative is likely to drop slightly above 79.7
M in 2024.
Xeris Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Xeris Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Xeris Pharmaceuticals fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to
measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.